Gongwin Biopharm Holdings
6617.TWO
3.56 USD
0.03
+0.85%
g
Overview
Last close
3.56 usd
Market cap
403.15M usd
52 week high
6.84 usd
52 week low
2.99 usd
Target price
N/A usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
457.0509
Price/Book Value
4.5503
Enterprise Value
372.32M usd
EV/Revenue
384.1088
EV/EBITDA
-167.232
Key financials
Revenue TTM
969301.19 usd
Gross Profit TTM
548397.92 usd
EBITDA TTM
-4.40M usd
Earnings per Share
-0.02 usd
Dividend
N/A usd
Total assets
N/A usd
Net debt
N/A usd
About
Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs. It is developing PTS302, which has completed Phase III clinical trials for the treatment of lung cancer; PTS100, which is in Phase II clinical trials for the treatment of liver cancer; PTS-02 for the treatment of adenoid cystic carcinoma; and PTS500 for the treatment of malignant pleural effusion. The company was founded in 2014 and is based in Taipei, Taiwan.
- Symbol6617.TWO
- ExchangeTWO
- IsinN/A
- CountryTaiwan
- SectorHealthcare
- IndustryBiotechnology
- CEO
- HeadquarterTaipei
- Web sitehttps://www.gongwinbiopharm.com
